Experiments
In Vivo Anesthetic Exposure. For tumor growth experiments, male and female wild-type (WT) C57BL/6 mice, male C57BL/6 RAG1 −/− mice, or male C57BL/6 RAG2 −/− × γ c −/− mice between 8 and 12 weeks of age were injected subcutaneously into the right flank with 1 × 10 6 cells of the melanoma cell line B16F1ova harvested at approximately 80% confluence. After injection, mice were anesthetized with 1%-1.5% of vaporized isoflurane (Fluriso [VetOne, Boise, ID], M1000 [Supera Anesthesia Innovations, Clackamas, OR] or SurgiVet Vaporizer [Smiths Medical, Minneapolis, MN]) in oxygen in a Plexiglas (Evonik Performance Materials GmbH, Essen, Germany) chamber while continuously monitored. Their body temperature was maintained by using a temperature-controlled pad. Mice were subsequently emerged and kept at our facility for the remainder of the experimental time as described above. Tumors were measured blinded whenever possible on day 7, 10, and 13/14 unless the tumor size exceeded the permitted parameters by our animal protection protocol in which case the animals were euthanized before the end of the experiment to alleviate suffering. Tumor size was recorded on the day of assessment and/or on the day of euthanization.
In Vitro Anesthetic Exposure. For examining the impact of isoflurane on the tumor directly, B16 melanoma cells were exposed either for 2 hours to 1%-1.5% of isoflurane in an incubator chamber with continuous 5% carbon dioxide-air mix gas flow (Billups-Rothenberg, Inc, San Diego, CA) or to
The impact of volatile anesthetics on cancer progression has been observed for decades, but sex differences have not been described. Male and female immune systems vary considerably, and the immune system plays an important role in limiting cancer growth. Currently, mouse models describing the impact of volatile anesthetics on cancer growth are limited to same-sex models. In this brief report, we describe a sex-specific impact of isoflurane on melanoma growth observed in wild-type but not in immune-deficient mice. Future experimental designs related to anesthesia and cancer should evaluate the biological variable of sex in a systematic manner. 
Statistics
Changes of tumor size over time and difference of such changes between experimental and control as well as between male and female mice were modeled using the generalized estimating equations (GEEs), in which treatment (isoflurane versus control, with control serving as the reference group), time (day 7, 10, and 14, with day 7 serving as reference level), sex (male versus female, with female serving as reference level), and their interactions formed the predictors. If there were significant interactions between 2 (or 3) factors, we assessed factor effects within levels of the ) (Ctrl n = 7/group; Iso n = 4-6/group). D, Furthermore, in vitro exposure of tumor cells to isoflurane before implantation did not lead to differences between female and male mice (Ctrl male n = 4-9/group; Ctrl female n = 9/group; Iso male n = 5-10/group; Iso female n = 10/ group). In all experiments, a significant effect of time confirmed overall tumor growth (A-D). Data are presented as dot plots for individual "n" at each time point and shown as mean and 95% CI. Results were considered significant when P ≤ .05. *P ≤ .05, **P ≤ .01. CI indicates confidence interval; Ctrl, control; Iso, isoflurane; NK, natural killer.
www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA E BRIEF REPORT interacting factor(s). If no significant interaction was present between any factors, we reported main effects for each factor collapsing over the other factors. The semiparametric GEEs require no distribution assumption, providing valid inference for a broad class of data distribution. 7 All analyses were set at type I error α = .05.
Before fitting the GEEs, missing data were imputed for those that were euthanized due to large tumors by using the largest observed tumor size at assessments on the day of their euthanization (n = 1 in the control group and n= 4 in the isoflurane group for the WT in vivo experiments and n = 1 in the female control group in the in vitro experiments). Missing data due to any other reason unrelated to tumor growth were not imputed (n = 1 for 1 mouse in the male in vivo control group that was euthanized due to fighting injuries). We also imputed data for the mice that were euthanized using the last observation carried forward method. Because results from the 2 methods are quite similar, we only report the ones from the first approach.
The sample size of the male mice was able to detect a large between-group effect size (Cohen d = 0.88) with 80% power and a 2-sided α = .05. The actual effect size observed in our data was d = 0.96 for the difference between the isofluraneexposed group and control group at day 14 within the male mice, slightly exceeding the detectable effect size. Power was actually larger than indicated by the power analysis because of modeling the repeated assessments using the GEEs.
RESULTS
Overall, we observed that melanoma grew faster in male mice treated with isoflurane compared to control male mice. This effect was not seen in female mice. Given the potential impact of time, sex, and treatment group, we proceeded to perform a GEE analysis to formally test the impact of these parameters on tumor growth rate. The GEEs showed significant main effects (P < .001 for time, P = .003 for treatment groups, and P < .001 for sex), 2-way interactions (P < .05 for time-by-treatment, P < .001 for time-by-sex, and P = .016 for treatment-by-sex), and 3-way interaction (P = .038). As expected, tumor size increased significantly over time (significant increase from day 7 to day 10 [P < .001; confidence interval {CI}, 38.6-78.0] and to day 14 [P < .001; CI, 42.7-121.5]), but no significant difference in tumor growth was seen between the male and female mice in the control group (P = .37; CI, −40.4 to 25.1 at day 10, and P = .89; CI, −15.3 to 108.5 at day 14). Within the females, there was no significant difference between the isoflurane-exposed group and control group (P = .37; CI, −34.4 to 12.8 at day 10, and P = .89; CI, −46.3 to 53.1 at day 14). Within the male group, there was a significantly higher increase in the isoflurane group (P = .01; CI, 13.7-107.7 at day 10, and P = .042; CI, 2.9-159.1 at day 14), compared to the control group. The specific effect of isoflurane in male but not in female mice is indicated in the Figure, To further corroborate this concept, the tumor cells were exposed to 2 hours of 1%-1.5% isoflurane in vitro before tumor injection, thereby limiting the anesthetic exposure to cancer cells and not immune cells or any other host cells. When applied to these in vitro data, the GEEs showed significant main effect of time (P < .001), but no significant difference in main effect of isoflurane treatment (P = .93), main effect of sex (P = .25), time-by-treatment interaction (P = .58), time-by-sex interaction (P = .26), treatment-by-sex interaction (.29), and time-by-treatment-by-sex interaction (.47). The lack of direct isoflurane effect on tumor growth shown in the Figure D for the observed tumor sizes for male and female mice across all time points again indicates an immune system-dependent mechanism rather than a direct anesthetic effect on melanoma cells.
DISCUSSION
Our observational studies demonstrate that isoflurane impacts melanoma growth in male mice only when an intact immune system is present, while no such effects on tumor growth occurred in WT, immune-competent female mice. A direct effect of isoflurane on tumor cells was proposed previously, 8 but this was not apparent on our melanoma model: tumor growth was not affected if the tumor was exposed to isoflurane before transplantation into WT males or females. The effect of inhalational anesthetics on tumor progression via its impact on the immune system has been studied and discussed in mice and humans. 9 Mouse models have previously demonstrated a detrimental effect of inhalational anesthetics on tumor spread. 6, 10 Interestingly, published literature on the effect of anesthesia exclusively used male rodent models 10 or does not specify sex of mice, 6 and the effect of sex in this process has not been reported. Differences in male and female immune functions are well established, and our understanding of their clinical implications is expanding rapidly. 4 Little attention, however, has been directed to examine sex-specific effects of anesthetics and how these relate to cancer progression. Our results indicate that male and female immune function may be affected differently by anesthetics, and further studies taking not only sex, but also phases of the female estrous cycle into account are warranted. We do not suggest that human women are not affected by the detrimental effects of anesthesia on the immune system, and an effect of inhalational anesthetics on cancer growth in human women should not be excluded. In fact, human clinical studies examining the benefits of intravenous anesthesia versus inhalational anesthesia found benefits in avoiding volatiles in both men and women, and additional studies describing the benefits of regional anesthesia demonstrate such effects in males as well as in females. 11 When studying the effects of volatile anesthesia on the immune system and their subsequent effect on cancer growth, especially in murine models, careful consideration should be given to the sex of the species being studied and comparative experiments are warranted when working with both rodent and human samples. E
